Saposin C

DB17380InvestigationalProtein Based Therapies

Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. BXQ-350 consists of Saposin C and the... BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.

Mechanism: Pharmacologically active on Lysosomal acid glucosylceramidase
Curator reviewed
Also known as: BXQ-350 · SAPOSIN C (NON-GLYCOSYLATED) · SAPOSIN C RECOMBINANT

Resolves to

Compound

UNII2N62LTC861

Targets

P04062GBA1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Saposin C, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account